A 24-year-old unmarried woman from Delhi presents with amenorrhea for 8 months and progressive weight gain over 2 years. On examination: BMI 28 kg/m², hirsutism (Ferriman–Gallwey score 12), acne, and acanthosis nigricans. Pelvic ultrasound shows bilateral polycystic ovaries. Serum LH:FSH ratio is 3.2:1, fasting insulin 18 mIU/L, and fasting glucose 92 mg/dL. What is the most appropriate next step in management?

Explanation

## Clinical Context This patient has PCOS with clinical and biochemical features (elevated LH:FSH, hyperinsulinemia, hirsutism, acne, acanthosis nigricans). The presence of **acanthosis nigricans and elevated fasting insulin (18 mIU/L)** signals **insulin resistance**, which is present in 50–70% of PCOS patients and carries significant metabolic risk. ## Why OGTT is the Next Step **Key Point:** Before initiating any PCOS-specific therapy, metabolic screening is mandatory in all PCOS patients, especially those with clinical signs of insulin resistance (acanthosis nigricans, central obesity, elevated fasting insulin). **High-Yield:** PCOS is associated with: - Impaired glucose tolerance (IGT): 30–40% of PCOS patients - Type 2 diabetes: 10% of PCOS patients - Metabolic syndrome: 40–50% of PCOS patients OGTT is the gold standard for detecting **impaired fasting glucose (IFG)** and **impaired glucose tolerance (IGT)** — conditions that may be missed by fasting glucose alone (her fasting glucose is 92 mg/dL, which is normal, but OGTT will unmask post-load hyperglycemia). ## Management Algorithm ```mermaid flowchart TD A[PCOS diagnosed with signs of insulin resistance]:::outcome --> B[Perform OGTT + assess metabolic syndrome]:::action B --> C{OGTT result?}:::decision C -->|Normal glucose tolerance| D[Lifestyle + metformin if BMI >25 or metabolic syndrome]:::action C -->|IGT or IFG| E[Metformin + lifestyle modification]:::action C -->|Diabetes| F[Metformin + refer endocrinology]:::action D --> G[Manage menstrual irregularity: OCP or progestin]:::action E --> G F --> G ``` **Clinical Pearl:** Acanthosis nigricans is a **clinical marker of severe insulin resistance** and warrants aggressive metabolic screening and early intervention to reduce cardiovascular and diabetes risk. ## Why This Comes Before Other Treatments | Step | Timing | Rationale | |------|--------|----------| | **OGTT + metabolic screening** | **First** | Identifies glucose dysregulation and metabolic syndrome; guides intensity of intervention | | Metformin ± lifestyle | Second | Addresses insulin resistance; improves ovulatory function | | OCP or progestin | Second/Third | Manages menstrual irregularity and hirsutism; not first-line if metabolic disease present | | Ovarian drilling | Last resort | Reserved for clomiphene-resistant anovulation; not indicated for metabolic management | **Tip:** NEET PG frequently tests the **sequence of PCOS management**. Always screen for metabolic disease *before* starting hormonal therapy.